What is generalized anxiety disorder?

Generalized anxiety disorder (GAD) is a persistent mental health condition characterized by excessive, difficult-to-control worry across multiple life domains, accompanied by physical symptoms such as restlessness, fatigue, difficulty concentrating, irritability, muscle tension, and sleep disturbance. Per DSM-5, the worry must be present for at least six months and cause clinically significant distress or functional impairment.

Lifetime prevalence in the US adult population is approximately 5.7%, with 12-month prevalence around 3.1%, per Kessler et al. 2005 in the National Comorbidity Survey Replication. Prevalence is higher in primary care settings (7-10%), in women (roughly twice the male rate), and in adults aged 30-50.

How is GAD different from normal worry?

Normal worry is typically focused on identifiable concerns, transient, proportionate to the actual situation, and does not significantly impair daily functioning. GAD-level worry is persistent (at least 6 months), excessive relative to the actual concern, difficult to control, generalized across multiple domains rather than focused on one issue, and causes meaningful impairment in work, relationships, or self-care.

Is GAD the same as panic disorder?

No. Panic disorder is characterized by recurrent unexpected panic attacks — discrete episodes of intense fear with somatic symptoms peaking within minutes. GAD is characterized by chronic, lower-intensity but persistent worry. The two conditions are highly comorbid but diagnostically distinct.

How is GAD diagnosed?

Diagnosis requires a clinical interview by a qualified mental health professional using DSM-5 or ICD-11 criteria. Self-screening instruments like the GAD-7 can identify probable GAD with good sensitivity and specificity but are not diagnostic on their own.

Can I screen myself for GAD?

Yes — the LifeByLogic Anxiety Test implements the validated GAD-7 (Spitzer 2006), the most widely-used brief anxiety screen. A score of 10 or higher has 89% sensitivity and 82% specificity for GAD per the original validation. The screen is a starting point for clinical conversation, not a diagnosis.

Generalized Anxiety Disorder (GAD) — definition and overview

1. The definition

Generalized anxiety disorder (GAD) is one of the most common mental health conditions worldwide. It is characterized by persistent, excessive, and difficult-to-control worry about multiple aspects of daily life — work, relationships, health, finances, the future — accompanied by physical and behavioral symptoms that cause meaningful interference with day-to-day functioning.

Unlike situational anxiety, which is a normal and adaptive response to identifiable threats, GAD-level worry is persistent across at least six months, excessive in proportion to the actual concern, generalized rather than focused on one specific issue, and clinically impairing rather than transient.

The GAD-7 is the most widely-used brief screening instrument for this condition.

2. DSM-5 diagnostic criteria

The Diagnostic and Statistical Manual of Mental Disorders (5th edition; American Psychiatric Association, 2013) defines GAD by these criteria:

Excessive anxiety and worry occurring more days than not for at least 6 months, about a number of events or activities (such as work or school performance).
The person finds it difficult to control the worry.
The anxiety and worry are associated with three (or more) of the following six symptoms (only one required in children):
- Restlessness or feeling keyed up or on edge
- Being easily fatigued
- Difficulty concentrating or mind going blank
- Irritability
- Muscle tension
- Sleep disturbance (difficulty falling or staying asleep, or restless, unsatisfying sleep)
The anxiety, worry, or physical symptoms cause clinically significant distress or impairment in social, occupational, or other important areas of functioning.
The disturbance is not attributable to the physiological effects of a substance (e.g., a drug of abuse, a medication) or another medical condition (e.g., hyperthyroidism).
The disturbance is not better explained by another mental disorder.

Diagnosis requires a clinical interview by a qualified mental health professional. Self-report instruments cannot establish a DSM-5 diagnosis.

3. Prevalence and onset

Measure	Estimate	Source
US lifetime prevalence (adult)	≈ 5.7%	Kessler et al. 2005, NCS-R
US 12-month prevalence (adult)	≈ 3.1%	Kessler et al. 2005, NCS-R
Primary care prevalence	≈ 7-10%	Kroenke et al. 2007
Female:male ratio	≈ 2:1	Kessler et al. 2005
Median age of onset	≈ 31 years	Kessler et al. 2005

GAD onset is later than most other anxiety disorders, with peak incidence in mid-life. The condition is chronic — without treatment, remission rates are modest (around 38% at 12 years per longitudinal studies). With evidence-based treatment, remission rates improve substantially.

4. Distinction from related conditions

GAD shares features with other anxiety disorders and depression, leading to high comorbidity:

Panic disorder involves recurrent unexpected panic attacks — discrete episodes of intense fear with rapid somatic symptoms peaking within minutes. GAD is the chronic background; panic is the acute foreground.
Social anxiety disorder involves fear of social or performance situations specifically. GAD worry is more diffuse and not focused on social evaluation.
PTSD involves anxiety following traumatic experience, with intrusion symptoms (flashbacks, nightmares), avoidance, and altered arousal. GAD does not require traumatic precipitant.
Major depressive disorder shares fatigue, sleep disturbance, and concentration problems with GAD; the two are comorbid in ~60% of cases per Kessler 2005.
Obsessive-compulsive disorder involves intrusive thoughts (obsessions) and compulsive behaviors that the person feels driven to perform. GAD worry is more diffuse and not paired with compulsions.

The GAD-7 is also reasonably sensitive to panic disorder, social anxiety disorder, and PTSD per Kroenke et al. 2007 — meaning a high score on the screen warrants multi-domain follow-up, not just GAD-specific evaluation.

5. Treatment approaches

GAD is highly treatable. First-line evidence-based treatments include:

Cognitive Behavioral Therapy (CBT) — large effect sizes per Hofmann et al. 2012 meta-analysis (269 studies). CBT for GAD targets worry-control through cognitive restructuring, exposure to uncertainty, and behavioral experiments.
Mindfulness-Based Stress Reduction (MBSR) — moderate effect per Goyal et al. 2014 JAMA Internal Medicine meta-analysis.
Internet-delivered CBT (iCBT) — equivalent efficacy to face-to-face CBT per Andrews et al. 2018 meta-analysis. Programs include MoodGYM, Mind-Spot, and others.
SSRIs and SNRIs — first-line pharmacological treatment. Sertraline, escitalopram, paroxetine, venlafaxine, duloxetine all have RCT support.
Cardiovascular exercise — moderate-to-large effect per Stonerock et al. 2015 meta-analysis. Likely most effective for somatic-dominant presentations.
Unified Protocol for transdiagnostic treatment — Barlow et al. 2017. Targets shared mechanisms across anxiety disorders rather than disorder-specific symptoms.

Treatment selection often depends on symptom profile (cognitive-dominant vs somatic-dominant vs behavioral-dominant), comorbidity pattern, and patient preference. The Anxiety Test surfaces this profile and matches to evidence-supported intervention class.

6. Related concepts

7. References

American Psychiatric Association. (2013). Diagnostic and Statistical Manual of Mental Disorders (5th ed.). DSM-5. APA Publishing.
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Merikangas, K. R., & Walters, E. E. (2005). Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Archives of General Psychiatry, 62(6), 593–602. doi.org/10.1001/archpsyc.62.6.593
Kroenke, K., Spitzer, R. L., Williams, J. B. W., Monahan, P. O., & Löwe, B. (2007). Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection. Annals of Internal Medicine, 146(5), 317–325. doi.org/10.7326/0003-4819-146-5-200703060-00004
Spitzer, R. L., Kroenke, K., Williams, J. B. W., & Löwe, B. (2006). A brief measure for assessing generalized anxiety disorder: the GAD-7. Archives of Internal Medicine, 166(10), 1092–1097. doi.org/10.1001/archinte.166.10.1092
Hofmann, S. G., Asnaani, A., Vonk, I. J. J., Sawyer, A. T., & Fang, A. (2012). The efficacy of cognitive behavioral therapy: a review of meta-analyses. Cognitive Therapy and Research, 36(5), 427–440. doi.org/10.1007/s10608-012-9476-1
Goyal, M., Singh, S., Sibinga, E. M. S., Gould, N. F., et al. (2014). Meditation programs for psychological stress and well-being: a systematic review and meta-analysis. JAMA Internal Medicine, 174(3), 357–368. doi.org/10.1001/jamainternmed.2013.13018
Stonerock, G. L., Hoffman, B. M., Smith, P. J., & Blumenthal, J. A. (2015). Exercise as treatment for anxiety: systematic review and analysis. Annals of Behavioral Medicine, 49(4), 542–556. doi.org/10.1007/s12160-014-9685-9
Andrews, G., Basu, A., Cuijpers, P., Craske, M. G., et al. (2018). Computer therapy for the anxiety and depression disorders. Journal of Anxiety Disorders, 55, 70–78. doi.org/10.1016/j.janxdis.2018.01.001
Barlow, D. H., Farchione, T. J., Sauer-Zavala, S., et al. (2017). Unified Protocol for Transdiagnostic Treatment of Emotional Disorders: Therapist Guide (2nd ed.). Oxford University Press.